Literature DB >> 12636352

Fasciola hepatica: surface and internal tegumental changes induced by treatment in vitro with the sulphoxide metabolite of albendazole ('Valbazen').

J F Buchanan1, I Fairweather, G P Brenna, A Trudgett, E M Hoey.   

Abstract

A morphological study has been carried out to determine the effect of the active sulphoxide metabolite of the benzimidazole anthelmintic, albendazole (ABZ-SO) on the adult liver fluke, Fasciola hepatica. Whole flukes were treated with ABZ-SO for 12 and 24 h at a concentration of 10 microg/ml. The changes in response to drug treatment were examined by scanning electron microscopy (SENI), transmission electron microscopy (TEM) and tubulin immunocytochemistry (ICC). No surface changes were apparent following 12 h ABZ-SO treatment, but localized blebbing was observed after 24 h, which became more extensive towards the posterior region of both surfaces. TEM of sections from the posterior midbody region revealed that ABZ-SO caused the accumulation of secretory bodies in the tegumental cells and in their cytoplasmic connections and, after 24 h, just above the basal plasma membrane. Localized blebbing of the apical membrane also occurred. The morphology of the Golgi complexes within the tegumental cells began to change after 12 h treatment with ABZ-SO and, by 24 h, few complexes were observed. A distinct increase in tubulin immunoreactivity occurred after 12 h treatment, but this decreased after 24 h. The results obtained are consistent with those expected for microtubule inhibition. They are discussed in relation to the action of established microtubule inhibitors, as well as the benzimidazole derivative, triclabendazole.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12636352     DOI: 10.1017/s0031182002002664

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  18 in total

1.  Fasciola hepatica: tegumental surface alterations following treatment in vivo and in vitro with nitroxynil (Trodax).

Authors:  B McKinstry; I Fairweather; G P Brennan; A B Forbes
Journal:  Parasitol Res       Date:  2003-08-22       Impact factor: 2.289

2.  Fasciola hepatica: effects of the fasciolicide clorsulon in vitro and in vivo on the tegumental surface, and a comparison of the effects on young- and old-mature flukes.

Authors:  M Meaney; I Fairweather; G P Brennan; L S L McDowell; A B Forbes
Journal:  Parasitol Res       Date:  2003-08-22       Impact factor: 2.289

3.  Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  Catherine Devine; Gerard P Brennan; Carlos E Lanusse; Luis I Alvarez; Alan Trudgett; Elizabeth Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2010-03-25       Impact factor: 2.289

4.  Ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo and in vitro drug treatment with nitroxynil (Trodax).

Authors:  B McKinstry; G P Brennan; L Halferty; A B Forbes; I Fairweather
Journal:  Parasitol Res       Date:  2007-06-08       Impact factor: 2.289

5.  Surface changes in adult Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha.

Authors:  M McConville; G P Brennan; A Flanagan; R E B Hanna; H W J Edgar; R Castillo; A Hernández-Campos; I Fairweather
Journal:  Parasitol Res       Date:  2009-05-21       Impact factor: 2.289

6.  Senna alexandrina Mill. induced ultrastructural changes on Hymenolepis diminuta.

Authors:  S Kundu; S Roy; S Nandi; B Ukil; Larisha Mawkhlieng Lyndem
Journal:  J Parasit Dis       Date:  2016-04-09

7.  Liver fluke β-tubulin isotype 2 binds albendazole and is thus a probable target of this drug.

Authors:  Emma Chambers; Louise A Ryan; Elizabeth M Hoey; Alan Trudgett; Neil V McFerran; Ian Fairweather; David J Timson
Journal:  Parasitol Res       Date:  2010-07-31       Impact factor: 2.289

8.  Immature triclabendazole-resistant Fasciola hepatica: tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.

Authors:  M McConville; G P Brennan; M McCoy; R Castillo; A Hernandez-Campos; F Ibarra; I Fairweather
Journal:  Parasitol Res       Date:  2006-10-03       Impact factor: 2.289

9.  Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.

Authors:  C Devine; G P Brennan; C E Lanusse; L I Alvarez; A Trudgett; E Hoey; I Fairweather
Journal:  Parasitol Res       Date:  2011-03-26       Impact factor: 2.289

10.  The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica.

Authors:  Mark W Robinson; Jill Lawson; Alan Trudgett; Elizabeth M Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2003-12-03       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.